Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects.
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis B vaccine recombinant
- Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 04 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2012 Actual patient number is 1212 as reported by ClinicalTrials.gov.
- 10 Feb 2012 Planned end date changed from 1 Sep 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.